What is SS-31?
SS-31 is a synthetic tetrapeptide that has been investigated for its interactions with mitochondria. Its amino-acid sequence is commonly written as D-Arg-Dmt-Lys-Phe-NH2, with Dmt referring to 2,6-dimethyltyrosine. Unlike many peptides studied through conventional cell-surface receptors, SS-31 has attracted research interest because of its association with the inner mitochondrial membrane and the phospholipid cardiolipin.
What is elamipretide?
Elamipretide is the name used for the compound developed from SS-31 research. It has also appeared in scientific literature under development names including Bendavia and MTP-131. Elamipretide has progressed beyond basic laboratory research into human clinical studies investigating several disorders involving mitochondrial dysfunction.
The existence of human studies is important when assessing the evidence, but it does not mean that every proposed mitochondrial effect demonstrated experimentally has been established as a clinical effect.
SS-31 vs elamipretide terminology
SS-31 and elamipretide generally refer to the same core peptide rather than two unrelated compounds. SS-31 is particularly common in earlier experimental and preclinical literature, while elamipretide became the principal name used during pharmaceutical development and clinical investigation.
Other names encountered in publications include MTP-131 and Bendavia. Researchers reviewing the literature should therefore consider these terms when searching for studies, while also checking the precise formulation and experimental conditions used.
Mitochondrial membranes and cardiolipin
Cardiolipin is a distinctive phospholipid concentrated within the inner mitochondrial membrane. It contributes to membrane organisation and interacts with proteins involved in mitochondrial energy production.
SS-31 has been investigated for its interaction with cardiolipin-containing membranes. Experimental research suggests this interaction can influence the physical environment surrounding components of the mitochondrial respiratory machinery. This proposed relationship between SS-31 and cardiolipin is central to much of the mechanistic research surrounding the peptide.
Mitochondrial bioenergetics
Mitochondria generate much of a cell's usable energy through oxidative phosphorylation. Electrons pass through the mitochondrial respiratory chain, helping establish a proton gradient across the inner mitochondrial membrane that ultimately supports ATP synthesis.
SS-31 research has examined whether interactions with the inner mitochondrial membrane can influence respiratory-chain efficiency, membrane organisation and ATP-related bioenergetics under experimental conditions. These investigations are particularly relevant to models in which mitochondrial function has been disrupted, although results depend strongly on the biological model being studied.
Oxidative-stress research
Mitochondria are both important producers of reactive oxygen species and vulnerable targets of oxidative damage. Excessive oxidative stress can affect mitochondrial proteins, lipids and DNA and can interfere with normal cellular energy metabolism.
SS-31 has therefore been investigated in experimental models involving mitochondrial oxidative stress. Research has examined changes in reactive oxygen species, lipid oxidation, mitochondrial membrane properties and respiratory function. These findings are useful for understanding possible mechanisms but should not automatically be interpreted as evidence of therapeutic antioxidant effects in humans.
Cellular, animal and human research
SS-31 has been investigated across cellular experiments, animal models and human clinical studies. In-vitro research has helped explore interactions involving cardiolipin, mitochondrial membranes and respiratory processes, while animal studies have examined these mechanisms within more complex biological systems.
Elamipretide has also entered human clinical development, including studies involving mitochondrial and cardiovascular disorders. Human trials provide a substantially different level of evidence from laboratory or animal experiments, but results remain specific to the disease, population, formulation and endpoints actually studied.
SS-31 vs MOTS-c
SS-31 and MOTS-c are both associated with mitochondrial research, but they represent fundamentally different types of peptides.
SS-31 is a synthetic mitochondria-targeting tetrapeptide investigated particularly for interactions involving cardiolipin and the inner mitochondrial membrane. MOTS-c is a naturally occurring mitochondrial-derived peptide encoded within mitochondrial DNA and has been studied primarily as a signalling molecule associated with cellular metabolism and stress responses.
The fact that both appear in mitochondrial research does not mean that they share the same mechanism, biological targets or evidence base.
Evidence limitations
One challenge with SS-31 research is the large range of experimental models in which the peptide has been investigated. A mitochondrial effect observed in isolated cells or a specific animal disease model cannot automatically establish that the same effect occurs in humans.
Clinical evidence for elamipretide must also be interpreted according to the particular condition and endpoints examined. Evidence concerning pharmaceutical-grade elamipretide in a controlled clinical trial should not automatically be attributed to independently produced materials labelled SS-31.
Distinguishing mechanistic evidence, preclinical findings and clinical outcomes is therefore particularly important when assessing claims surrounding this peptide.
Frequently asked questions
Is SS-31 the same as elamipretide?
SS-31 is the research designation associated with the peptide that was subsequently developed under the name elamipretide. Other names encountered in the literature include MTP-131 and Bendavia.
What is cardiolipin?
Cardiolipin is a specialised phospholipid found predominantly within the inner mitochondrial membrane. It contributes to mitochondrial membrane organisation and interacts with proteins involved in cellular energy production.
Does SS-31 target mitochondria?
SS-31 is described as a mitochondria-targeting peptide because experimental research has demonstrated its association with mitochondrial membranes and cardiolipin. The precise biological consequences of this interaction depend on the experimental context.
Is SS-31 the same as MOTS-c?
No. SS-31 is a synthetic tetrapeptide, whereas MOTS-c is a mitochondrial-derived peptide encoded within mitochondrial DNA. Their proposed mechanisms and research backgrounds are substantially different.
Has elamipretide been studied in humans?
Yes. Elamipretide has undergone human clinical investigation. However, the existence of clinical trials does not establish every proposed effect of SS-31, and findings must be interpreted according to the particular population, condition and endpoints studied.
Scientific references
Scientific literature on SS-31 can be found under several names, including SS-31, elamipretide, MTP-131 and Bendavia. References should distinguish mechanistic studies involving mitochondrial membranes and cardiolipin from animal experiments and controlled human clinical trials, with conclusions limited to the specific models and outcomes investigated.